Brainstorm Cell Therapeutics Appoints Former FDA Associate Commissioner to Board

summarizeSummary

Brainstorm Cell Therapeutics appointed former FDA Associate Commissioner Peter Pitts to its board, a strategic move to bolster regulatory efforts for its critical Phase 3b ALS trial, which recently received an unprecedented FDA Special Protocol Assessment.

check_boxKey Events · Executive and Board Changes · BCLI

• New Director Appointment

  Peter Pitts, former FDA Associate Commissioner and a globally recognized expert in healthcare policy and regulatory science, has been appointed to the Board of Directors, increasing the board size from seven to eight.

• Strategic Regulatory Expertise

  Mr. Pitts brings over 30 years of healthcare public policy and FDA experience, which is crucial for guiding the company's lead ALS therapy, NurOwn®, through the regulatory process.

• Timing with Critical ALS Trial

  The appointment coincides with the company's preparation to initiate its Phase 3b ENDURANCE trial for ALS under a recently executed FDA Special Protocol Assessment (SPA), the first ever granted for an ALS therapeutic candidate.

• Director Compensation

  Mr. Pitts received an option to purchase up to 150,000 shares of the company's common stock, with half vesting upon issuance and the remainder vesting in six months.

auto_awesomeAnalysis · BCLI · Life Sciences

Brainstorm Cell Therapeutics, a micro-cap biotech company facing severe financial distress and an explicit going concern warning, has strategically appointed Peter Pitts, a former FDA Associate Commissioner, to its Board of Directors. This move is critical as the company prepares to initiate its Phase 3b ALS trial under an unprecedented FDA Special Protocol Assessment (SPA). Mr. Pitts' extensive regulatory expertise is vital for navigating the complex FDA approval process for their lead therapy, NurOwn®, and signals a focused effort to enhance regulatory strategy at a pivotal time for the company's survival.